Patents by Inventor Yuan-Ruei Huang

Yuan-Ruei Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220312162
    Abstract: An information converting method and a system thereof are configured to convert a first information into a second information. An information obtaining step is performed to obtain the first information corresponding to a first communication protocol and transmit the first information to a converter. The first information includes a first access layer sub-information and an upper-layer protocol sub-information. A first access layer removing step is performed to drive the converter to remove the first access layer sub-information from the first information according to a converting process. A second access layer adding step is performed to drive the converter to add a second access layer sub-information corresponding to a second communication protocol to the first information and combine the second access layer sub-information with the upper-layer protocol sub-information according to the converting process, so that the first information is converted into the second information.
    Type: Application
    Filed: July 5, 2021
    Publication date: September 29, 2022
    Inventors: Chun-Nan CHEN, Yuan-Ruei HUANG, Chao-Sheng LIN
  • Publication number: 20220227728
    Abstract: The present invention discloses a series of nuclear medicine tracers that are combined with brain microtubule-associated protein Tau targeting compounds to produce a group of compounds of nuclear medicine that can be utilized for imaging of microtubule-associated protein Tau. When the positrons released by the decay encounter the electrons of the cells in the sample, utilizing the positron decay characteristics of fluorine-18 or iodine-124 isotope to generate mutual destruction reactions, a pair of opposite gamma rays is formed which are imaged by positron emission tomography. The compounds can be applied for the in vivo detection of microtubule-associated protein Tau deposits in the brain. The invention provides a strategy for diagnosis of Alzheimer's disease and a method to measure the efficacy of therapeutic drugs targeting microtubule-associated protein Tau.
    Type: Application
    Filed: January 19, 2021
    Publication date: July 21, 2022
    Inventors: MING-HSIN LI, KAI-HUNG CHENG, SHENG-NAN LO, SHIH-WEI LO, YUAN-RUEI HUANG, JENN-TZONG CHEN
  • Publication number: 20220089574
    Abstract: The structure and preparation method of a compound D-L2(-B)-L1-A is disclosed, A is a physiologically and pharmacologically active molecule that physically binds to a specific biological molecule or receptor; L1 is a variable structure with the molecular connection activity at both ends connecting to A and L2; L2 is a variable structure, which has three-terminal molecular connection activity connecting to L1, D and B; B is a physiologically and pharmacologically active molecule that binds to albumin, changing the A molecule in the body cyclic characteristics; D is a polycarboxylic macrocyclic structure that binds to radioisotopes; D-L2(-B)-L1-A compound can be used to express chemokine receptor 4 (CXCR4) receptors on cells, tissues, and/or organs, and after binding with radionuclides, it is suitable for detection of CXCR4 protein binding in vitro, detection of CXCR4 cell binding in vitro or detection of CXCR4 expression in in vivo animal imaging.
    Type: Application
    Filed: September 22, 2020
    Publication date: March 24, 2022
    Inventors: MING-HSIN LI, SHENG-NAN LO, SHIH-WEI LO, SHIH-YING LEE, SU-JUNG CHEN, WEI-LIN LO, MING-WEI CHEN, YUAN-RUEI HUANG
  • Patent number: 11077217
    Abstract: The present invention provides a radioactive labeling method for neuropeptide Y (NPY) compound and a mammalian diagnostic radioactive targeting medicine with NPY peptide being modified at position 27th to 36th, and after binding with the chelating agent and labeling the radiation nucleus 66Ga67Ga68Ga177Lu or 111In to provide a radioactive targeting medicine for multi-type breast cancer diagnosis and treatment.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: August 3, 2021
    Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH, ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN
    Inventors: Ming-Hsin Li, Su-Jung Chen, Ming-Wei Chen, Yuan-Ruei Huang, Shih-Ying Lee, Chun-Fang Feng, Sheng-Nan Lo, Chih-Hsien Chang
  • Publication number: 20200237938
    Abstract: The present invention provides a radioactive labeling method for neuropeptide Y (NPY) compound and a mammalian diagnostic radioactive targeting medicine with NPY peptide being modified at position 27th to 36th, and after binding with the chelating agent and labeling the radiation nucleus 66Ga, 67Ga, 68Ga, 177Lu or 111In to provide a radioactive targeting medicine for multi-type breast cancer diagnosis and treatment.
    Type: Application
    Filed: December 11, 2018
    Publication date: July 30, 2020
    Inventors: Ming-Hsin Li, Su-Jung Chen, Ming-Wei Chen, Yuan-Ruei Huang, Shih-Ying Lee, Chun-Fang Feng, Sheng-Nan Lo, Chih-Hsien Chang
  • Publication number: 20200129646
    Abstract: A radioactive labeled long-acting peptide-targeting pharmaceutical and production method, in which the peptide targeted pharmaceutical is firstly dissolved in a solution, followed by labeling the radioactive at a high temperature, and the dosage of the pharmaceutical with radioactive labeling is expected to be reduced and labeling efficiency is improved, and no further purification by filtration is required, which shortens the preparation process and reduces personnel exposure in the working environment. The radioactive labeled long-acting peptide-targeting pharmaceutical can increase the specific binding capacity of tumors and reduce the non-specific accumulation in normal tissues. It can be applied to the field of tumor and nuclear medicine for diagnosis and treatment of tumors and/or tumor metastases with efficacy and precision treatment.
    Type: Application
    Filed: October 31, 2018
    Publication date: April 30, 2020
    Inventors: Ming-Hsin Li, Chih-Hsien Chang, Su-Jung Chen, Shih-Ying Lee, Sheng-Nan Lo, Ming-Wei Chen, Yuan-Ruei Huang, Chun-Fang Feng, Shih-Wei Lo, Cheng-Hui Chuang
  • Publication number: 20160016958
    Abstract: Flumazenil (FMZ) is labeled with fluorine(F)-18 to obtain F-18-flumazenil. F-18-flumazenil can be strongly combined with type-A acceptor of gamma-aminobutyric acid (GABAA) in brain for tracing. The time and temperature for labeling is saved and lowered. The toxic chemical, acetonitrile, used in separation and purification can be prevented. The present invention has a simplified procedure for evaluating mental disease medicines in a short time. Moreover, time for developing medicines for treating related diseases of the central nervous system can be reduced.
    Type: Application
    Filed: July 17, 2014
    Publication date: January 21, 2016
    Inventors: Kai-Hung Cheng, Yean-Hung Tu, Li-Yuan Huang, Yuan-Ruei Huang, Kang-Wei Chang
  • Patent number: 9017646
    Abstract: A process of evaluating blood-brain barrier permeability of a stroke rat by using fluorescent substance is disclosed. This process uses an Evans blue dye having spontaneous fluorescence properties, in combination with the use of a new non-invasive in vivo imaging system (IVIS), to obtain fluorescent signals so as to assess the change in the blood-brain barrier permeability of rodents after a cerebral artery stroke model surgery. In operation, an Evans blue dye is injected into a stroke rat of middle cerebral artery occlusion model. A non-invasive in vivo imaging system is used to detect the fluorescence distribution of the whole brain, and obtain images combined by the fluorescence images and optical images for the whole brain tissue. Thereby, the change in the blood-brain barrier permeability of the stroke rat can be completely realized.
    Type: Grant
    Filed: July 10, 2012
    Date of Patent: April 28, 2015
    Assignee: Institute of Nuclear Energy Research, Atomic Energy Council
    Inventors: Jun-Ming Shih, Yuan-Ruei Huang, Yu-Lung Wu, Shih-Ying Lee, Kang-Wei Chang, Chia-Chien Chen
  • Publication number: 20140017173
    Abstract: A process of evaluating blood-brain barrier permeability of a stroke rat by using fluorescent substance is disclosed. This process uses an Evans blue dye having spontaneous fluorescence properties, in combination with the use of a new non-invasive in vivo imaging system (IVIS), to obtain fluorescent signals so as to assess the change in the blood-brain barrier permeability of rodents after a cerebral artery stroke model surgery. In operation, an Evans blue dye is injected into a stroke rat of middle cerebral artery occlusion model. A non-invasive in vivo imaging system is used to detect the fluorescence distribution of the whole brain, and obtain images combined by the fluorescence images and optical images for the whole brain tissue. Thereby, the change in the blood-brain barrier permeability of the stroke rat can be completely realized.
    Type: Application
    Filed: July 10, 2012
    Publication date: January 16, 2014
    Applicant: ATOMIC ENERGY COUNCIL-INSTITUTE OF NUCLEAR ENERGY RESEARCH
    Inventors: Jun-Ming Shih, Yuan-Ruei Huang, Yu-Lung Wu, Shih-Ying Lee, Kang-Wei Chang, Chia-Chien Chen